Indian Journal of Respiratory Care

IJRC Email      Register      Login

VOLUME 11 , ISSUE 2 ( April-June, 2022 ) > List of Articles

Original Article

Pulmonary Rehabilitation Reduces the Sarcopenia Phenotype in Patients with Chronic Obstructive Pulmonary Disease

Abdulla Altamimi, Aesha Shuaeeb, Ahmed Yakout, Dana Hassouna, Huda Srouji, Maha AlQaydi, Mona Mohammed Mahmoud, Noor Alkindi, Qamar Kashmoola, Ragad Alkhatib, Rand Soudan, Roaa Abu Tawileh

Keywords : 8-isoprostanes, chronic obstructive pulmonary disease, C-reactive protein, handgrip strength, pulmonary rehabilitation, sarcopenia

Citation Information : Altamimi A, Shuaeeb A, Yakout A, Hassouna D, Srouji H, AlQaydi M, Mahmoud MM, Alkindi N, Kashmoola Q, Alkhatib R, Soudan R, Tawileh RA. Pulmonary Rehabilitation Reduces the Sarcopenia Phenotype in Patients with Chronic Obstructive Pulmonary Disease. Indian J Respir Care 2022; 11 (2):162-168.

DOI: 10.4103/ijrc.ijrc_20_22

License: CC BY-NC-SA 4.0

Published Online: 06-12-2022

Copyright Statement:  Copyright © 2022; Indian Journal of Respiratory Care.


Purpose: Sarcopenia or age-associated muscle decline is common in patients with chronic obstructive pulmonary disease (COPD). Pulmonary rehabilitation (PR) is an effective tool in reducing COPD phenotype, but its effects on sarcopenia and functional capacity are poorly known. We aimed to assess the restorative potential of PR on skeletal muscle and physical capacity in COPD patients. Methods: We investigated the male COPD patients, 56-71 years old (n = 55), through clinical examination, laboratory investigation, and spirometry. All patients were evaluated at two time points, 1 year apart before and following the PR. Reduced handgrip strength (HGS), appendicular skeletal mass index (ASMI), and gait speed were considered the clinical indexes of Sarcopenia. Enzyme-linked immunosorbent assay were used to measure the circulating markers of inflammation (C-reactive protein [CRP]) and oxidative stress (8-isoprostanes). Results: At baseline, the COPD patients had low HGS and gait speed and elevated CRP and 8-isoprostanes levels. According to four internationally recognized criteria, these patients also had a high incidence of Sarcopenia. One year of PR partially restored the HGS, gait speed, CRP, and 8-isoprostanes levels (all P < 0.05). However, the ASMI values were insignificantly restored following PR. PR also reduced the incidence of sarcopenia in COPD patients. Among various criteria for sarcopenia, the international working group on sarcopenia yielded the highest incidence of sarcopenia in COPD patients. Conclusion: Altogether, our data show the therapeutic potential of PR in skeletal muscle, physical performance, and systemic health in patients with COPD.

  1. Morley JE, Baumgartner RN, Roubenoff R, Mayer J, Nair KS. Sarcopenia. J Lab Clin Med 2001;137:231-43.
  2. Cruz-Jentoft AJ, Landi F, Schneider SM, Zúñiga C, Arai H, Boirie Y, et al. Prevalence of and interventions for sarcopenia in ageing adults: A systematic review. Report of the International Sarcopenia Initiative (EWGSOP and IWGS). Age Ageing 2014;43:748-59.
  3. Cruz-Jentoft AJ, Baeyens JP, Bauer JM, Boirie Y, Cederholm T, Landi F, et al. Sarcopenia: European consensus on definition and diagnosis: Report of the European working group on sarcopenia in older people. Age Ageing 2010;39:412-23.
  4. Lee SH, Gong HS. Measurement and interpretation of handgrip strength for research on sarcopenia and osteoporosis. J Bone Metab 2020;27:85-96.
  5. Bae EJ, Park NJ, Sohn HS, Kim YH. Handgrip strength and all-cause mortality in middle-aged and older Koreans. Int J Environ Res Public Health 2019;16:740.
  6. Qaisar R, Karim A, Muhammad T, Shah I. Circulating biomarkers of accelerated sarcopenia in respiratory diseases. Biology (Basel) 2020;9:322.
  7. Han Y, Wu Z, Chen Y, Kan Y, Geng M, Xu N, et al. Factors associated with appendicular skeletal muscle mass among male Chinese patients with stable chronic obstructive pulmonary disease: A hospital-based cross-sectional study. Medicine (Baltimore) 2019;98:e17361
  8. Middleton A, Fritz SL, Lusardi M. Walking speed: The functional vital sign. J Aging Phys Act 2015;23:314-22.
  9. Qaisar R, Karim A, Muhammad T. Plasma CAF22 levels as a useful predictor of muscle health in patients with chronic obstructive pulmonary disease. Biology (Basel) 2020;9:166. [doi:10.3390/biology9070166].
  10. Mathur S, Brooks D, Carvalho CR. Structural alterations of skeletal muscle in copd. Front Physiol 2014;5:104.
  11. Barreiro E, Jaitovich A. Muscle atrophy in chronic obstructive pulmonary disease: Molecular basis and potential therapeutic targets. J Thorac Dis 2018;10:S1415-24.
  12. Lee SY, Tung HH, Liu CY, Chen LK. Physical activity and sarcopenia in the geriatric population: A systematic review. J Am Med Dir Assoc 2018;19:378-83.
  13. Beaudart C, Dawson A, Shaw SC, Harvey NC, Kanis JA, Binkley N, et al. Nutrition and physical activity in the prevention and treatment of sarcopenia: Systematic review. Osteoporos Int 2017;28:1817-33.
  14. Yoo SZ, No MH, Heo JW, Park DH, Kang JH, Kim SH, et al. Role of exercise in age-related sarcopenia. J Exerc Rehabil 2018;14:551-8.
  15. Arnold MT, Dolezal BA, Cooper CB. Pulmonary rehabilitation for chronic obstructive pulmonary disease: Highly effective but often overlooked. Tuberc Respir Dis (Seoul) 2020;83:257-67.
  16. Corhay JL, Dang DN, Van Cauwenberge H, Louis R. Pulmonary rehabilitation and COPD: Providing patients a good environment for optimizing therapy. Int J Chron Obstruct Pulmon Dis 2014;9:27-39.
  17. Sahin H, Varol Y, Naz I, Aksel N, Tuksavul F, Ozsoz A. The effect of pulmonary rehabilitation on COPD exacerbation frequency per year. Clin Respir J 2018;12:165-74.
  18. Blervaque L, Préfaut C, Forthin H, Maffre F, Bourrelier M, Héraud N, et al. Efficacy of a long-term pulmonary rehabilitation maintenance program for COPD patients in a real-life setting: A 5-year cohort study. Respir Res 2021;22:79.
  19. Korkmaz C, Demirbas S, Vatansev H, Yildirim E, Teke T, Zamani A. Effects of comprehensive and intensive pulmonary rehabilitation and nutritional support on quality of life and functional status in patients with chronic obstructive pulmonary disease. J Int Med Res 2020;48. [doi: 10.1177/0300060520919567].
  20. Qaisar R, Karim A, Muhammad T, Shah I, Khan J. Prediction of sarcopenia using a battery of circulating biomarkers. Sci Rep 2021;11:8632.
  21. Gupta N, Malhotra N, Ish P. GOLD 2021 guidelines for COPD - What's new and why. Adv Respir Med 2021;89:344-6.
  22. Qaisar R, Karim A, Muhammad T. Circulating biomarkers of handgrip strength and lung function in chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis 2020;15:311-21.
  23. Han CH, Chung JH. Association between hand grip strength and spirometric parameters: Korean National Health and Nutrition Examination Survey (KNHANES). J Thorac Dis 2018;10:6002-9.
  24. Jones SE, Maddocks M, Kon SS, Canavan JL, Nolan CM, Clark AL, et al. Sarcopenia in COPD: Prevalence, clinical correlates and response to pulmonary rehabilitation. Thorax 2015;70:213-8.
  25. Lan CC, Chu WH, Yang MC, Lee CH, Wu YK, Wu CP. Benefits of pulmonary rehabilitation in patients with COPD and normal exercise capacity. Respir Care 2013;58:1482-8.
  26. Hallin R, Janson C, Arnardottir RH, Olsson R, Emtner M, Branth S, et al. Relation between physical capacity, nutritional status and systemic inflammation in COPD. Clin Respir J 2011;5:136-42.
  27. Lakhdar R, McGuinness D, Drost EM, Shiels PG, Bastos R, MacNee W, et al. Role of accelerated aging in limb muscle wasting of patients with COPD. Int J Chron Obstruct Pulmon Dis 2018;13:1987-98.
  28. Berry MJ, Sheilds KL, Adair NE. Comparison of effects of endurance and strength training programs in patients with COPD. COPD 2018;15:192-9.
  29. Higashimoto Y, Ando M, Sano A, Saeki S, Nishikawa Y, Fukuda K, et al. Effect of pulmonary rehabilitation programs including lower limb endurance training on dyspnea in stable COPD: A systematic review and meta-analysis. Respir Investig 2020;58:355-66.
  30. Barnes PJ. Oxidative stress-based therapeutics in COPD. Redox Biol 2020;33:101544.
  31. Saeki C, Takano K, Oikawa T, Aoki Y, Kanai T, Takakura K, et al. Comparative assessment of sarcopenia using the JSH, AWGS, and EWGSOP2 criteria and the relationship between sarcopenia, osteoporosis, and osteosarcopenia in patients with liver cirrhosis. BMC Musculoskelet Disord 2019;20:615. [doi:10.1186/s12891-019-2983-4].
  32. Bijlsma AY, Meskers CG, Ling CH, Narici M, Kurrle SE, Cameron ID, et al. Defining sarcopenia: The impact of different diagnostic criteria on the prevalence of sarcopenia in a large middle aged cohort. Age (Dordr) 2013;35:871-81.
  33. Meza-Valderrama D, Marco E, Dávalos-Yerovi V, Muns MD Tejero-Sánchez M, Duarte E, et al. Sarcopenia, malnutrition, and cachexia: Adapting definitions and terminology of nutritional disorders in older people with cancer. Nutrients 2021;13:761.
  34. Studenski SA, Peters KW, Alley DE, Cawthon PM, McLean RR, Harris TB, et al. The FNIH sarcopenia project: Rationale, study description, conference recommendations, and final estimates. J Gerontol A Biol Sci Med Sci 2014;69:547-58.
  35. Bianchi L, Maietti E, Abete P, Bellelli G, Bo M, Cherubini A, et al. Comparing EWGSOP2 and FNIH sarcopenia definitions: Agreement and 3-year survival prognostic value in older hospitalized adults: The GLISTEN study. J Gerontol A Biol Sci Med Sci 2020;75:1331-7.
  36. Harris-Love MO, Benson K, Leasure E, Adams B, McIntosh V. The influence of upper and lower extremity strength on performance-based sarcopenia assessment tests. J Funct Morphol Kinesiol 2018;3:53.
  37. Alonso AC, Ribeiro SM, Luna NM, Peterson MD, Bocalini DS, Serra MM, et al. Association between handgrip strength, balance, and knee flexion/extension strength in older adults. PLoS One 2018;13:e0198185.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.